Aclaris Therapeutics, Inc.
ACRSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United. The $635.5M market capitalization puts ACRS squarely in small-cap range for its industry. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various di.
Market Cap
$635.5M
Beta
0.78
P/E (TTM)
—
P/E (Fwd)
-6.27
EPS (TTM)
$-0.56
EPS (Fwd)
$-0.73
ROE
-48.4%
ROA
-24.7%
Cash
$105.4M
Total Debt
$2.0M
Free CF
-$32.2M
52W Change
216.0%
Annual Financials
Cash vs Debt
Aclaris Therapeutics, Inc. holds $105.4M in cash against $2.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$32.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -48.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $29.8M (2022) to $7.8M (2025), a 74% decline worth watching.
With cash comfortably exceeding debt, ACRS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Aclaris Therapeutics, Inc. and its sector.